FDA Grants Approval for Olmesartan Medoxomil and Hydrochlorothiazide ANDA206371
The FDA has granted approval for ANDA206371, a combination of Olmesartan Medoxomil and Hydrochlorothiazide, submitted by Micro Labs.
Company
Pharmaceutical intelligence for Micro Labs with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.